Market Place
Sourcing Support
Nkarta Announces IND Clearance for Myasthenia Gravis Trial
05 Dec 2024 //
GLOBENEWSWIRE
Nkarta to Participate in an Upcoming Investor Conference
26 Nov 2024 //
GLOBENEWSWIRE
Nkarta to Participate in an Upcoming Investor Conference
12 Nov 2024 //
GLOBENEWSWIRE
Nkarta continues pivot to lupus by shelving lymphoma program
11 Nov 2024 //
FIERCE BIOTECH
Nkarta Reports Q3 2024 Financial Results & Corporate Highlights
07 Nov 2024 //
GLOBENEWSWIRE
Nkarta to Participate in Upcoming Investor Conference
03 Sep 2024 //
GLOBENEWSWIRE
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Nkarta Starts Trial Of NKX019 For Systemic Lupus Erythematosus
24 Jul 2024 //
GLOBENEWSWIRE
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
16 Jul 2024 //
GLOBENEWSWIRE
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis
27 Jun 2024 //
GLOBENEWSWIRE
Nkarta Adds Experienced Leader in Autoimmune R&D
13 Jun 2024 //
GLOBENEWSWIRE
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
09 May 2024 //
GLOBENEWSWIRE
Nkarta Announces Pricing of $240 Million Underwritten Offering
25 Mar 2024 //
GLOBENEWSWIRE
Nkarta`s blood cancer CAR stalls again, driving deprioritization
23 Mar 2024 //
FIERCE BIOTECH
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Nkarta Presents NKX101 Clinical Data at the 2023 Annual Meeting & Exposition
09 Dec 2023 //
GLOBENEWSWIRE
Nkarta to Participate at Upcoming Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Nkarta moves cell therapy into autoimmune trials, lays off staff
18 Oct 2023 //
FIERCE BIOTECH
Nkarta trims headcount as it sets sights on autoimmune cell therapy
17 Oct 2023 //
ENDPTS
Ex-Nkarta exec Nadir Mahmood to lead UCSF spinout Rezo
20 Sep 2023 //
FIERCE BIOTECH
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
10 Aug 2023 //
GLOBENEWSWIRE
Nkarta to Participate at Upcoming Investor Conference
03 Aug 2023 //
GLOBENEWSWIRE
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
05 Jul 2023 //
GLOBENEWSWIRE
NKX101 Demonstrates Early Activity in Relapsed/Refractory AML
27 Jun 2023 //
ONCOLIVE
Nkarta`s cell therapy needs specific pre-conditioning
27 Jun 2023 //
FIERCE BIOTECH
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101
26 Jun 2023 //
GLOBENEWSWIRE
Nkarta Presents NKX019 Data at European Hematology Association 2023
10 Jun 2023 //
GLOBENEWSWIRE
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at 2023 Congress
11 May 2023 //
GLOBENEWSWIRE
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
11 May 2023 //
GLOBENEWSWIRE
Nkarta to Participate at Upcoming Investor Conferences
12 Apr 2023 //
GLOBENEWSWIRE
Nkarta Announces Departure of Chief Financial & Business Officer
30 Mar 2023 //
GLOBENEWSWIRE
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
Nkarta to Participate at Upcoming Investor Conferences
09 Feb 2023 //
GLOBENEWSWIRE
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
09 Jan 2023 //
GLOBENEWSWIRE
Nkarta underscores safety of CAR-NK, boasts early responses
06 Dec 2022 //
ENDPTS
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
09 Nov 2022 //
GLOBENEWSWIRE
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies
07 Nov 2022 //
GLOBENEWSWIRE
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
11 Aug 2022 //
GLOBENEWSWIRE
Nkarta Announces Key Senior Leadership Team Appointments
25 Jul 2022 //
GLOBENEWSWIRE
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
16 May 2022 //
GLOBENEWSWIRE
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
12 May 2022 //
GLOBENEWSWIRE
Nkarta Announces Closing of Upsized Public Offering of Common Stock
28 Apr 2022 //
GLOBENEWSWIRE
Nkarta gives first look at two ‘natural killer’ cell therapies for blood cancer
26 Apr 2022 //
BIOPHARMADIVE
Nkarta Announces Pricing Of Upsized Public Offering Of Common Stock
25 Apr 2022 //
PRESS RELEASE
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered
25 Apr 2022 //
GLOBENEWSWIRE
Nkarta Announces Proposed Public Offering of Common Stock
25 Apr 2022 //
GLOBENEWSWIRE
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data NK Cell
22 Apr 2022 //
GLOBENEWSWIRE
Nkarta to Participate at Upcoming Investor Conference
08 Apr 2022 //
GLOBENEWSWIRE
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Nkarta Appoints Angela Thedinga, to Board of Directors
29 Mar 2022 //
GLOBENEWSWIRE
Nkarta Reports Q4 and FY 2021 Financial Results and Corporate Highlights
17 Mar 2022 //
GLOBENEWSWIRE
Nkarta to Present PC Data from Engineered NK Cell Platform at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101
16 Dec 2021 //
GLOBENEWSWIRE
Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH
13 Dec 2021 //
GLOBENEWSWIRE
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform
12 Nov 2021 //
GLOBENEWSWIRE
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th
01 Oct 2021 //
GLOBENEWSWIRE
Nkarta to Participate at Upcoming Investor Conference
14 Sep 2021 //
GLOBENEWSWIRE
On a roll, Nkarta plans for new headquarters, manufacturing site
15 Jul 2021 //
FIERCEPHARMA
On a roll, Nkarta plans for new headquarters, manufacturing site
14 Jul 2021 //
FIERCEPHARMA
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility
14 Jul 2021 //
GLOBENEWSWIRE
